Candidiasis, commonly known as thrush, is a fungal infection caused by a yeast (a type of fungus) called Candida. It commonly affects the mouth, throat, and vagina. Risk factors for candidiasis include a weakened immune system due to HIV/AIDS, cancer treatment, or antibiotics use. Candidiasis if left untreated can spread to other body parts and become life threatening. The global candidiasis market growth can be attributed to the increasing demand for therapeutic drugs to treat drug-resistant strains of Candida and rising prevalence of hospital-acquired
Key Takeaways
Key players operating in the Candidiasis market are Basilea Pharmaceutica Ltd, Astellas Pharma Inc., SCYNEXIS, Inc., NovaDigm Therapeutics, Mycovia Pharmaceuticals, Inc., Pfizer Inc, and Viatris Inc., among others. The key opportunities in the candidiasis market include the development of novel therapeutic drug classes targeting resistant strains and development of diagnostic tests for early detection. Rising prevalence of hospital-acquired candidiasis in developing regions presents lucrative opportunities for global expansion through strategic collaborations and licensing agreements.
Market Drivers and Restrain
The rising prevalence of hospital-acquired infections is one of the major Candidiasis Market Growth drivers fueling the candidiasis market growth. According to the Centers for Disease Control and Prevention (CDC), over 700,000 cases of hospital-acquired infections occur annually in the United States. Moreover, the ongoing COVID-19 pandemic has severely compromised the immune systems of patients, further increasing their susceptibility to opportunistic infections. This has resulted in a significant rise in hospital-acquired candidiasis globally. However, the availability of generic antifungal drugs and self-medication are some of the key factors hampering the market growth. Furthermore, the presence of alternative treatment options also poses a major challenge.
Segment Analysis
The candidiasis market can be segmented based on treatment type into antifungal drugs and antifungal vaccines. Among these, antifungal drugs dominate the market owing to a larger patient pool being treated with various drugs for candidiasis infections. Some of the commonly used antifungal drug classes prescribed are azoles, allylamines, and polyenes. Flucytosine is also prescribed in combinations with other drugs for severe systemic fungal infections.
Global Analysis
Regionally, North America holds the largest share in the candidiasis market due to increased per capita healthcare expenditure and higher diagnosis and treatment rates for fungal infections. However, Asia Pacific is anticipated to grow at the fastest pace during the forecast period owing to rising awareness about fungal diseases, increasing healthcare expenditures, and expanding medical tourism industry in the region. Additionally, presence of leading global market players is further expected to boost regional market growth in Asia Pacific through to 2031.
Get More Insights On This Topic: Candidiasis Market
Comments
0 comment